TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02480088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
Study: NCT01172444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Supporitory, Once Daily, Per Rectal for 6 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canasa
Description: Suppository, Once Daily, Per Rectal for 6 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suppository, Once Daily, Per Rectal for 6 Weeks
Study: NCT03218774

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Exercise Group
Description: The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Center Group
Description: The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
Study: NCT04564235

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genome-wide analyses
Description: genome-wide analyses will be done in patients and parents (father, mother)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Search for de novo mutations in paternal sperm samples
Description: Sperm analysis will be done in paternal samples
Study: NCT01056081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training.
Study: NCT01674504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium chewable tablets 4 mg and 5 mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study: NCT00042289

Intervention type: DRUG
Intervention: isoniazid
Description: isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
Study: NCT01674504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium chewable tablets 4 mg and 5 mg
Description: Montelukast sodium chewable tablets 4mg and 5mg
Study: NCT01466465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: given orally, once daily, before grass pollen season

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: middle-chain fatty acids (carrier)
Description: given orally, once daily, before grass pollen season
Study: NCT03225391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 0:00 to 3:00 hours
Description: A nap from 0:00 to 3:00 hours during a night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 0:00 to 3:00 hours
Description: A nap from 0:00 to 3:00 hours during a night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 3:00 to 6:00 hours
Description: A nap from 3:00 to 6:00 hours during a night shift.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap from 3:00 to 6:00 hours
Description: A nap from 3:00 to 6:00 hours during a night shift.
Study: NCT01136525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir Hydrochloride
Description: Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
Study: NCT04242706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETTEvac
Description: Endotracheal tube with evacuation lumen without noble metal coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIP ETTEvac
Description: Endotracheal tube with evacuation lumen with noble metal coating
Study: NCT00892008

Intervention type: DRUG
Intervention: Pregabalin
Description: Pregabalin 75-150 mg BID for at least 2 weeks.
Study: NCT05130372

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Relaxation Method Group- Roller Massage
Description: A theraband roller massager (Theraband®, The Hygenic Corporation, Akron, OH) was used for the myofascial relaxation method.
Study: NCT04521309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody based IVIG therapy
Description: Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody based IVIG therapy
Description: Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics
Study: NCT00003851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gonzalez regimen
Study: NCT01721343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in an individualized conditioning program with an RCM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Participate in an individualized conditioning program with an RCM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo enhanced usual care with an RCM
Study: NCT01752647

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low dose computed tomography
Description: Low dose computed tomography scan
Study: NCT00551031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
Description: 0.1 mL, Intradermal (ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)
Description: 0.1 mL, Intradermal (ID)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
Description: 0.5 mL, Intramuscular (IM)
Study: NCT04521309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody based IVIG therapy
Description: Patient groups will receive IVIG prepared from pooled convalescent plasma from recovered COVID-19 patients. This will be administered sequentially and in varying dosages, infused over a period of 12 hours, intravenously.Additionally, all treatment groups will receive same standard care as control group. Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics
Study: NCT00551031

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Description: 0.5 mL, Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
Description: 0.5 mL, Intramuscular (IM)
Study: NCT05940506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-2.5 mg (0.25%)/60 mL BID
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-5 mg (5%)/60 mL QD
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX-826-5 mg (5%)/60 mL BID
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm), starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered once in the morning and once in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application, 7 sprays (approximately 1 mL)/time, in the target area of the scalp (8 cm × 8 cm),starting from the center of the affected area, and massage with hands for 3-5 min. This dose is used regardless of the size of the affected area. It should be used when hair and scalp are completely dry. Wash hands after use. The control product will be administered in the evening once daily for QD dose groups, and once in the morning and once in the evening for the BID dose groups.
Study: NCT00983866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Telephone Counseling
Description: The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
Study: NCT01774812

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: 0.25 mcg 3x per week for 6 weeks
Study: NCT00003875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous or syngeneic stem cell rescue
Study: NCT03757351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Repeating oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Repeating oral dose
Study: NCT01774812

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: 0.25 mcg 3x per week for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 50,000IU 1x per week for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: 50,000IU 1x per week for 6 weeks
Study: NCT03722472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 + GLA-SE
Description: The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
Study: NCT02877069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VYC-12 HA injectable gel
Description: VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
Study: NCT00047502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonafarnib (SCH66336)
Description: Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day.
Study: NCT04009239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Consuming energy during a short interval during the day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Consuming energy during a short interval during the day
Study: NCT00042289

Intervention type: DRUG
Intervention: isoniazid
Description: isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

Intervention type: DRUG
Intervention: isoniazid
Description: isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.

Intervention type: DRUG
Intervention: pyrazinamide
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.

Intervention type: DRUG
Intervention: pyrazinamide
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.

Intervention type: DRUG
Intervention: pyrazinamide
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.

Intervention type: DRUG
Intervention: pyrazinamide
Description: pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.

Intervention type: DRUG
Intervention: kanamycin
Description: kanamycin (2nd line TB drug)

Intervention type: DRUG
Intervention: amikacin
Description: amikacin (2nd line TB drug)

Intervention type: DRUG
Intervention: capreomycin
Description: capreomycin (2nd line TB drug)

Intervention type: DRUG
Intervention: moxifloxacin
Description: moxifloxacin (2nd line TB drug)

Intervention type: DRUG
Intervention: levoflaxacin
Description: levofloxacin (2nd line TB drug)
Study: NCT00665678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: treatment for three months with paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment for three months with placebo
Study: NCT00323531

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest tube with tPA infusion for 3 days
Description: fibrinolysis through the chest tube
Study: NCT03357666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT(Glucose 200mg/Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Glucose 400mg/Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Glucose 400mg)
Description: Vaginal administration, two tablets once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUDC_VT (Sodium chloride 200mg)
Description: Vaginal administration, two tablets once a day for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal administration, two tablets once a day for 7 days
Study: NCT00042289

Intervention type: DRUG
Intervention: ofloxacin
Description: ofloxacin (2nd line TB drug)
Study: NCT00323531

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS decortication
Description: thoracoscopic decortication
Study: NCT00042289

Intervention type: DRUG
Intervention: ethionamide/prothionamide
Description: ethionamide/prothionamide (2nd line TB drug)

Intervention type: DRUG
Intervention: terizidone/cycloserine
Description: terizidone/cycloserine (2nd line TB drug)

Intervention type: DRUG
Intervention: para-aminosalicylic acid (PAS)
Description: para-aminosalicylic acid (PAS) (2nd line TB drug)

Intervention type: DRUG
Intervention: high dose INH
Description: high dose INH (2nd line TB drug)

Intervention type: DRUG
Intervention: bedaquiline
Description: bedaquiline (2nd line TB drug)

Intervention type: DRUG
Intervention: clofazamine
Description: clofazamine (2nd TB drug)

Intervention type: DRUG
Intervention: delamanid
Description: delamanid (2nd line TB drug)

Intervention type: DRUG
Intervention: linezolid
Description: linezolid (2nd line TB drug)

Intervention type: DRUG
Intervention: pretomanid
Description: pretomanid (2nd line TB drug)

Intervention type: DRUG
Intervention: ethinyl estradiol
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol

Intervention type: DRUG
Intervention: ethinyl estradiol
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol

Intervention type: DRUG
Intervention: ethinyl estradiol
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol

Intervention type: DRUG
Intervention: ethinyl estradiol
Description: oral contraceptives formulated with 30-35 μg ethinyl estradiol

Intervention type: DRUG
Intervention: etonogestrel implant
Description: etonogestrel implant contraceptive

Intervention type: DRUG
Intervention: etonogestrel implant
Description: etonogestrel implant contraceptive

Intervention type: DRUG
Intervention: etonogestrel implant
Description: etonogestrel implant contraceptive

Intervention type: DRUG
Intervention: etonogestrel implant
Description: etonogestrel implant contraceptive

Intervention type: DRUG
Intervention: nevirapine
Description: nevirapine 200 mg twice a day

Intervention type: DRUG
Intervention: nevirapine
Description: nevirapine 200 mg twice a day

Intervention type: DRUG
Intervention: amprenavir
Description: amprenavir 1200mg twice a day
Study: NCT02174016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Study: NCT01051115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
Study: NCT01825226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced-Homestead Food Production Program
Description: Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
Study: NCT00505804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
Study: NCT02185248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Action Plan
Description: The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
Study: NCT03638557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritious Lunch
Description: The intervention package consists of the following;~1. Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~2. Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein
Study: NCT03305757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artiss
Description: Application of ARTISS Glue to skin flaps after mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vicryl sutures
Description: Flap fixation with vicryl sutures after mastectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional closure after mastectomy
Study: NCT01721343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo enhanced usual care with an RCM
Study: NCT02866526

Intervention type: OTHER
Intervention: Patient questionnaire
Description: quantitative and qualitative data collection will be proposed.

Intervention type: OTHER
Intervention: Patient questionnaire
Description: quantitative and qualitative data collection will be proposed.
Study: NCT03487484

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire for gastrointestinal tract
Description: To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire for gastrointestinal tract
Description: To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire
Description: To assess quality of life, the SF-36 questionnaire will be applied

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaire
Description: To assess quality of life, the SF-36 questionnaire will be applied